Back to top

vaccines: Archive

Sundeep Ganoria

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

MRNANegative Net Change NVAXNegative Net Change SRPTNegative Net Change CRSPNegative Net Change PCVXPositive Net Change

Zacks Equity Research

GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

GSKNegative Net Change ANIPPositive Net Change CTMXNegative Net Change ETNBPositive Net Change

Sundeep Ganoria

Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNANegative Net Change

Zacks Equity Research

Here's Why Moderna Stock Soared 16% on Wednesday

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

PFEPositive Net Change MRNANegative Net Change BNTXPositive Net Change

Shaun Pruitt

Buy Johnson & Johnson (JNJ) Stock for Higher Highs?

Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.

JNJNegative Net Change PFEPositive Net Change LLYNegative Net Change ABBVPositive Net Change

Bryan Hayes

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

During this time of heightened market volatility, it pays to be invested in the right places.

GILDNegative Net Change

Zacks Equity Research

Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.

SNYNegative Net Change NVONegative Net Change NVAXNegative Net Change

Ahan Chakraborty

What's in Store for These 5 Biotech Stocks This Earnings Season?

Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.

PRGONegative Net Change NVAXNegative Net Change NTLANegative Net Change IOVANegative Net Change VTRSPositive Net Change